PROTEUS研究亚组分析:围手术期阿帕鲁胺联合ADT使高危前列腺癌复发风险降低62%
Perioperative Therapy Tops Prostatectomy Alone in High-Risk Prostate Cancer
PROTEUS III期研究的一项substudy在ESMO大会展示,高危局部前列腺癌患者在根治性前列腺切除术前后各6个月的阿帕鲁胺联合雄激素剥夺治疗(ADT),相比单纯手术将3年无事件生存的主要终点大幅改善,复发或死亡风险降低62%。
III期PROTEUS研究亚组分析显示,围手术期阿帕鲁胺联合雄激素剥夺治疗可使高危局部前列腺癌患者复发或死亡风险降低62%,为临床治疗策略选择提供关键证据。
— PROTEUS substudy shows a 62% lower risk of recurrence or death with apalutamide plus ADT
by Gregory Laub, Senior Director, Video, MedPage Today
November 12, 2026 • 3 min read
Results from a substudy of the phase III PROTEUS trial presented at the European Society for Medical Oncology (ESMO) congress showed that adding apalutamide (Erleada) and androgen-deprivation therapy (ADT) before and after radical prostatectomy reduced the risk of recurrence or death by 62% compared with prostatectomy alone in patients with high-risk localized prostate cancer.
In this exclusive MedPage Today video, Mary-Ellen Taplin, MD, of Dana-Farber Cancer Institute in Boston, discusses the findings.
Following is a transcript of her remarks:
At ASCO 2026 in the plenary, the PROTEUS main study was presented, which was a very large, 2,100-patient study, which looked at the effect of 6 months of neoadjuvant apalutamide and ADT compared to placebo and ADT, followed by prostatectomy. And then everyone received another 6 months of the therapy they had been assigned to. So that study was positive. It showed a 20% reduction in metastasis or death by central imaging review and a 26% reduction by investigator assessment.
And to complement that data, there was a substudy done, which was what was presented at ESMO during one of the oral sessions. So the substudy compared what I'll refer to as the PROTEUS regimen, so 6 months of ADT and apalutamide before and after prostatectomy to standard-of-care prostatectomy alone. There was a 3:1 randomization to the prostatectomy alone to obtain more patients for a comparison to the prostatectomy.
So the primary endpoint of the substudy was a little bit different than the primary endpoints of the main study. So the main study had two co-primary endpoints, which was pathologic response and MFS (metastasis-free survival). The primary endpoint of the substudy was event-free survival at 3 years. So event-free survival includes relapse by any means -- so PSA [prostate-specific antigen], local recurrence, [and] imaging relapse, which included PSMA [prostate-specific membrane antigen] PET or conventional imaging.
So this primary endpoint was very, very positive. There was a 62% reduction in the risk of recurrence or death with the 6 months of apalutamide and ADT before and after surgery, prostatectomy. And this was true controlling over time for the analysis at the longer time points when accounting for testosterone recovery. In addition, there was a 51% lower risk of death or metastasis -- again, metastasis by PSMA PET or conventional imaging. Fifty percent fewer patients received subsequent therapy at all by 3 years. And importantly, there was a 50% reduction in any radiation after receiving the neoadjuvant ADT and apalutamide. So in summary, the primary endpoint, event-free survival, and all the secondary endpoints including MFS and first subsequent therapy were all very positive for the combined neoadjuvant apalutamide, ADT, and prostatectomy.
Safety is very important to assess. The main side effects were similar, I would say, to what is known for apalutamide and ADT. Can't be ignored, but in general are easily managed in the clinic and include fatigue, hot flashes, and incidence of rash. The rash with apalutamide is different than a rash say with antibiotics. It's less of an allergic type rash and more immune-mediated where patients can continue the drug with a dose reduction or a short interruption.
Hypertension is a known class side effect of androgen pathway receptor inhibitors. Importantly, there was no increase in surgical complications. This is a nice study designed to analyze that with the neoadjuvant and the adjuvant therapy combined with prostatectomy compared to prostatectomy alone.
Notably, to me, is that in the control arm the patients who had prostatectomy, 70% of patients relapsed by 3 years. So these are men who -- prostatectomies alone are not curing them, and they need subsequent therapy which may or may not put them into remission.
So I think that's important to take into consideration when thinking about the best treatments for patients. You have to dissect the pros and cons of surgery, androgen deprivation, and radiation, and think about the general health of your patient, their age, their goals. Is ADT and an androgen pathway inhibitor safe? And is surgery versus radiation safe? And those are the types of analyses that the treating physician needs to make when thinking about these patients with very high-risk localized prostate cancer.
来源:MedPage Today · medpagetoday.com